Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis
Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis. Journal Of Clinical Oncology 2009, 27: 5112-5112. DOI: 10.1200/jco.2009.27.15_suppl.5112.Peer-Reviewed Original ResearchRenal cell carcinomaAI therapyAngiogenesis inhibitorsUS commercial health insurance claims databaseIV therapyAI groupTreatment of renal cell carcinomaCost of bevacizumabIntravenous bevacizumab treatmentTreated with sunitinibRetrospective claims database analysisHealth insurance claims databaseClaims database analysisInsurance Claims DatabaseTotal medical costsBevacizumab groupBevacizumab patientsBevacizumab treatmentCell carcinomaBevacizumabTreatment initiationSunitinibSorafenibTreatment periodOral administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply